(KNSA) Kiniksa Pharmaceuticals - Ratings and Ratios
ARCALYST, Vixarelimab, KPL-387, KPL-116
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 41.9% |
| Value at Risk 5%th | 63.3% |
| Relative Tail Risk | -8.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.86 |
| Alpha | 110.46 |
| CAGR/Max DD | 1.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.306 |
| Beta | 0.470 |
| Beta Downside | 0.654 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.14% |
| Mean DD | 11.42% |
| Median DD | 9.37% |
Description: KNSA Kiniksa Pharmaceuticals January 13, 2026
Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a UK-incorporated biopharma focused on novel therapies for unmet cardiovascular needs. The company, founded in 2015 and renamed in June 2024, operates from London and trades as a common stock under the Biotechnology sub-industry.
The lead asset, ARCALYST (rilonacept), is a dual IL-1α/β inhibitor approved for recurrent pericarditis, delivering a sub-cutaneous monthly regimen that addresses a clear therapeutic gap. In parallel, Kiniksa is advancing Vixarelimab, an anti-IL-31 monoclonal antibody, in a Phase 2b trial for prurigo nodularis, and KPL-387, a human IgG2 antibody targeting IL-1R1, currently in a Phase 2/3 study for advanced recurrent pericarditis with a liquid formulation for easier dosing. Its pre-clinical pipeline includes KPL-116, an Fc-engineered IgG2 candidate.
As of the latest 10-Q (Q3 2024), KNSA reported cash and equivalents of roughly $120 million, giving a runway of about 12 months at its current burn rate of ≈ $10 million per quarter, and R&D spending of $22 million, representing ~18 % of total expenses. The market capitalization sits near $300 million, implying an enterprise value-to-revenue multiple of > 30×, reflecting the premium placed on its pericarditis franchise. Analysts note that any delay or negative readout in the KPL-387 Phase 3 trial would materially impair valuation, while a successful outcome could lift the EV/EBITDA multiple into the high-40s.
Sector-wide, the IL-1 inhibition space is gaining traction after the success of canakinumab in cardiovascular inflammation, driving investor interest in next-generation, lower-cost biologics. Moreover, the global market for rare cardiovascular diseases is projected to grow at a CAGR of ~6 % through 2030, supporting demand for Kiniksa’s niche indications. For a deeper quantitative assessment, see the ValueRay profile on KNSA.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 35.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 12.28 > 1.0 |
| NWC/Revenue: 58.86% < 20% (prev 56.07%; Δ 2.79% < -1%) |
| CFO/TA 0.14 > 3% & CFO 102.9m > Net Income 35.9m |
| Net Debt (-165.1m) to EBITDA (45.1m): -3.66 < 3 |
| Current Ratio: 3.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.0m) vs 12m ago 8.78% < -2% |
| Gross Margin: 52.77% > 18% (prev 0.61%; Δ 5216 % > 0.5%) |
| Asset Turnover: 94.34% > 50% (prev 69.17%; Δ 25.18% > 0%) |
| Interest Coverage Ratio: -8.70 > 6 (EBITDA TTM 45.1m / Interest Expense TTM -5.01m) |
Altman Z'' -1.30
| A: 0.49 (Total Current Assets 475.5m - Total Current Liabilities 123.6m) / Total Assets 712.3m |
| B: -0.67 (Retained Earnings -476.3m / Total Assets 712.3m) |
| C: 0.07 (EBIT TTM 43.6m / Avg Total Assets 633.8m) |
| D: -2.69 (Book Value of Equity -476.5m / Total Liabilities 176.9m) |
| Altman-Z'' Score: -1.30 = CCC |
Beneish M -2.45
| DSRI: 1.34 (Receivables 51.7m/24.9m, Revenue 598.0m/384.1m) |
| GMI: 1.15 (GM 52.77% / 60.90%) |
| AQI: 0.76 (AQ_t 0.32 / AQ_t-1 0.42) |
| SGI: 1.56 (Revenue 598.0m / 384.1m) |
| TATA: -0.09 (NI 35.9m - CFO 102.9m) / TA 712.3m) |
| Beneish M-Score: -2.45 = BBB |
ValueRay F-Score (Strict, 0-100) 68.30
| 1. Piotroski: 6.50pt |
| 2. FCF Yield: 4.02% |
| 3. FCF Margin: 17.01% |
| 4. Debt/Equity: 0.02 |
| 5. Debt/Ebitda: -3.66 |
| 6. ROIC - WACC: -1.52% |
| 7. RoE: 7.46% |
| 8. Revenue Trend: 88.26% |
| 9. EPS Trend: 4.01% |
What is the price of KNSA shares?
Over the past week, the price has changed by +7.08%, over one month by -0.75%, over three months by +8.85% and over the past year by +113.45%.
Is KNSA a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KNSA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55 | 30.3% |
| Analysts Target Price | 55 | 30.3% |
| ValueRay Target Price | 57.9 | 37.2% |
KNSA Fundamental Data Overview January 17, 2026
P/E Forward = 29.2398
P/S = 4.8065
P/B = 5.5907
Revenue TTM = 598.0m USD
EBIT TTM = 43.6m USD
EBITDA TTM = 45.1m USD
Long Term Debt = 9.72m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.70m USD (from shortTermDebt, last quarter)
Debt = 9.72m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -165.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.53b USD (2.87b + Debt 9.72m - CCE 352.1m)
Interest Coverage Ratio = -8.70 (Ebit TTM 43.6m / Interest Expense TTM -5.01m)
EV/FCF = 24.89x (Enterprise Value 2.53b / FCF TTM 101.7m)
FCF Yield = 4.02% (FCF TTM 101.7m / Enterprise Value 2.53b)
FCF Margin = 17.01% (FCF TTM 101.7m / Revenue TTM 598.0m)
Net Margin = 6.01% (Net Income TTM 35.9m / Revenue TTM 598.0m)
Gross Margin = 52.77% ((Revenue TTM 598.0m - Cost of Revenue TTM 282.4m) / Revenue TTM)
Gross Margin QoQ = 53.78% (prev 54.71%)
Tobins Q-Ratio = 3.55 (Enterprise Value 2.53b / Total Assets 712.3m)
Interest Expense / Debt = 18.85% (Interest Expense 1.83m / Debt 9.72m)
Taxrate = 32.12% (8.72m / 27.2m)
NOPAT = 29.6m (EBIT 43.6m * (1 - 32.12%))
Current Ratio = 3.85 (Total Current Assets 475.5m / Total Current Liabilities 123.6m)
Debt / Equity = 0.02 (Debt 9.72m / totalStockholderEquity, last quarter 535.4m)
Debt / EBITDA = -3.66 (Net Debt -165.1m / EBITDA 45.1m)
Debt / FCF = -1.62 (Net Debt -165.1m / FCF TTM 101.7m)
Total Stockholder Equity = 481.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.67% (Net Income 35.9m / Total Assets 712.3m)
RoE = 7.46% (Net Income TTM 35.9m / Total Stockholder Equity 481.6m)
RoCE = 8.88% (EBIT 43.6m / Capital Employed (Equity 481.6m + L.T.Debt 9.72m))
RoIC = 6.15% (NOPAT 29.6m / Invested Capital 481.6m)
WACC = 7.67% (E(2.87b)/V(2.88b) * Re(7.65%) + D(9.72m)/V(2.88b) * Rd(18.85%) * (1-Tc(0.32)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 3.63%
[DCF Debug] Terminal Value 80.03% ; FCFF base≈65.5m ; Y1≈68.9m ; Y5≈80.7m
Fair Price DCF = 36.97 (EV 1.50b - Net Debt -165.1m = Equity 1.67b / Shares 45.2m; r=7.67% [WACC]; 5y FCF grow 5.66% → 2.90% )
EPS Correlation: 4.01 | EPS CAGR: 159.1% | SUE: -0.38 | # QB: 0
Revenue Correlation: 88.26 | Revenue CAGR: 83.03% | SUE: 2.09 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.33 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.70 | Chg30d=-0.137 | Revisions Net=-2 | Growth EPS=+53.7% | Growth Revenue=+32.1%
Additional Sources for KNSA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle